SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Vipoglanstat

Item No. 37925

CAS Registry No.: 1360622-01-0
Formal Name: 2-[[2,6-dichloro-3-[[(2,2-dimethyl-1-oxopropyl)amino]methyl]phenyl]amino]-6-(2,2-difluoroethoxy)-1-methyl-N-[*trans*-4-(trifluoromethyl)cyclohexyl]-1H-benzimidazole-5-carboxamide
Synonyms: BI 1029539, GS-248, OX-MPI
MF: $C_{30}H_{34}Cl_2F_5N_5O_3$
FW: 678.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vipoglanstat is supplied as a solid. A stock solution may be made by dissolving the vipoglanstat in the solvent of choice, which should be purged with an inert gas. Vipoglanstat is slightly soluble (0.1-1 mg/ml) in acetonitrile and sparingly soluble (1-10 mg/ml) in DMSO.

Description

Vipoglanstat is an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1; IC_{50} = ≤0.5 nM in isolated human whole blood).[1] It reduces LPS-induced increases in the influx of neutrophils and levels of cytokines in bronchoalveolar lavage fluid (BALF), as well as the expression of *PTGES*, the gene encoding mPGES-1, *Cox2*, and *Icam1* in the lung parenchyma, in a human *PTGES* knock-in mouse model of acute lung injury when administered at a dose of 30 mg/kg.[2] Vipoglanstat (30 mg/kg) also reduces the lung injury score and expression of *PTGES* and *Nos2*, the gene encoding inducible nitric oxide synthase (iNOS), as well as increases survival, in a human *PTGES* knock-in mouse model of sepsis induced by cecal ligation and puncture. It reduces status epilepticus-induced increases in brain capillary mPGES-1 and P-glycoprotein levels in a human *PTGES* knock-in mouse model of kainic acid-induced status epilepticus when administered at doses of 10, 30, and 100 mg/kg.[3]

References

1. Tornling, G., Edenius, C., Pauling, J.D., *et al.* A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's. *Rheumatology (Oxford)* (2024).
2. Gurusamy, M., Nasseri, S., Rampa, D.R., *et al.* Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice. *J. Transl. Med.* **19(1)**, 340 (2021).
3. Soldner, E.L.B., Hartz, A.M.S., Akanuma, S.I., *et al.* Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier. *FASEB J.* **33(12)**, 13966-13981 (2019).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM